ERBB2 and breast cancer: In this study, the pCR rates of both the HER2-0 and the HER2-low groups were significantly lower than the pCR rate of HER2 + BC reported in the literature [23], indicating that the lack of an effective therapeutic target for HER2-0 or HER2-low BC remains a barrier to the effectiveness of NACT.